glp-1 fatty liver disease Multiple target tissue effects of analogues on non-alcoholic (NAFLD) and non-alcoholic steatohepatitis (NASH) New Data of Semaglutide revels
Description
From a weight-inclusive perspective, the goal is not to shame or glorify these drugs, but to center informed consent, body autonomy, and holistic well-being
( 10.1007/s00125-017-4450-9) [DOI] [PubMed] [Google Scholar] Kahles F, Liberman A, Halim C, Rau M, Mollmann J, Mertens RW, Ruckbeil M, Diepolder I, Walla B, Diebold S, et al
Key Clinical Trial Data 1
Sung H, Ferlay J, Siegel RL, et al
Medical history, chronic health conditions, medication safety, and treatment goals are also important factors
